piracetam has been researched along with Complications, Pregnancy in 18 studies
Piracetam: A compound suggested to be both a nootropic and a neuroprotective agent.
| Excerpt | Relevance | Reference |
|---|---|---|
| "To review data evaluating levetiracetam management of epilepsy during pregnancy." | 8.85 | Levetiracetam use in pregnancy. ( Forinash, AB; Longo, B; Murphy, JA, 2009) |
| "This study, in a meaningful number of exposed pregnancies, confirms a low risk for MCM with levetiracetam monotherapy use in pregnancy." | 7.79 | Levetiracetam in pregnancy: results from the UK and Ireland epilepsy and pregnancy registers. ( Craig, J; Delanty, N; Hunt, SJ; Irwin, B; Liggan, B; Mawhinney, E; Morrison, PJ; Morrow, J; Parsons, L; Russell, A; Smithson, WH, 2013) |
| "Variations in the plasma concentration of levetiracetam during pregnancy and postpartum were prospectively monitored in five women to investigate their potential implications in epilepsy management and child outcome." | 7.75 | Levetiracetam plasma level monitoring during pregnancy, delivery, and postpartum: clinical and outcome implications. ( Cid, AO; Juste, AO; López-Fraile, IP; Modrego, PJ, 2009) |
| "To study pharmacokinetics of levetiracetam (LEV) during pregnancy, delivery, lactation, and in the neonatal period." | 7.74 | Pharmacokinetics of levetiracetam during pregnancy, delivery, in the neonatal period, and lactation. ( Ben-Menachem, E; Danielsson, B; Johansson, R; Källén, K; Luef, G; Ohman, I; Palm, R; Söderfeldt, B; Tomson, T, 2007) |
| " In Phase II/III trials, the adverse effects occurring more commonly in the treatment groups versus the placebo group were; somnolence (14." | 6.42 | Levetiracetam safety profiles and tolerability in epilepsy patients. ( Briggs, DE; French, JA, 2004) |
| "To review data evaluating levetiracetam management of epilepsy during pregnancy." | 4.85 | Levetiracetam use in pregnancy. ( Forinash, AB; Longo, B; Murphy, JA, 2009) |
| "Levetiracetam is a new generation antiepileptic drug used in treatment of patients with epilepsy and has adverse effects on different tissues." | 3.85 | Evaluation of apoptotic cell death on liver and kidney tissues following administration of levetiracetam during prenatal period. ( Ayas, B; Elbistan, M; Guvenc, T; Kara, N; Tekcan, A; Tural, S, 2017) |
| "To compare the cognitive and language development of children born to women with epilepsy (WWE) exposed in utero to levetiracetam (LEV) or sodium valproate (VPA) and control children born to women without epilepsy not taking medication during pregnancy." | 3.80 | In utero exposure to levetiracetam vs valproate: development and language at 3 years of age. ( Baker, GA; Bromley, RL; Cheyne, CP; García-Fiñana, M; Irwin, B; Morrow, J; Shallcross, R, 2014) |
| "This study, in a meaningful number of exposed pregnancies, confirms a low risk for MCM with levetiracetam monotherapy use in pregnancy." | 3.79 | Levetiracetam in pregnancy: results from the UK and Ireland epilepsy and pregnancy registers. ( Craig, J; Delanty, N; Hunt, SJ; Irwin, B; Liggan, B; Mawhinney, E; Morrison, PJ; Morrow, J; Parsons, L; Russell, A; Smithson, WH, 2013) |
| "Children born to women with epilepsy (WWE), exposed in utero to levetiracetam (LEV, n = 51), were assessed for early cognitive development and compared to children exposed to sodium valproate in utero (VPA, n = 44) and a group of children representative of the general population (n = 97)." | 3.77 | Child development following in utero exposure: levetiracetam vs sodium valproate. ( Baker, GA; Bonnett, LJ; Bromley, RL; Irwin, B; Morrow, J; Shallcross, R, 2011) |
| "Variations in the plasma concentration of levetiracetam during pregnancy and postpartum were prospectively monitored in five women to investigate their potential implications in epilepsy management and child outcome." | 3.75 | Levetiracetam plasma level monitoring during pregnancy, delivery, and postpartum: clinical and outcome implications. ( Cid, AO; Juste, AO; López-Fraile, IP; Modrego, PJ, 2009) |
| "To study pharmacokinetics of levetiracetam (LEV) during pregnancy, delivery, lactation, and in the neonatal period." | 3.74 | Pharmacokinetics of levetiracetam during pregnancy, delivery, in the neonatal period, and lactation. ( Ben-Menachem, E; Danielsson, B; Johansson, R; Källén, K; Luef, G; Ohman, I; Palm, R; Söderfeldt, B; Tomson, T, 2007) |
| " In Phase II/III trials, the adverse effects occurring more commonly in the treatment groups versus the placebo group were; somnolence (14." | 2.42 | Levetiracetam safety profiles and tolerability in epilepsy patients. ( Briggs, DE; French, JA, 2004) |
| " Pharmacokinetic changes associated with pregnancy may increase apparent clearance of extended-release formulations of levetiracetam, leading to periods of subtherapeutic blood or central nervous system concentrations." | 1.40 | Increased levetiracetam clearance associated with a breakthrough seizure in a pregnant patient receiving once/day extended-release levetiracetam. ( Garrity, LC; Standridge, SM; Turner, M, 2014) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 7 (38.89) | 29.6817 |
| 2010's | 11 (61.11) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Shallcross, R | 2 |
| Bromley, RL | 2 |
| Cheyne, CP | 1 |
| García-Fiñana, M | 1 |
| Irwin, B | 4 |
| Morrow, J | 4 |
| Baker, GA | 2 |
| Garrity, LC | 1 |
| Turner, M | 1 |
| Standridge, SM | 1 |
| Janszky, J | 1 |
| Vajda, FJE | 1 |
| O'Brien, TJ | 1 |
| Graham, J | 1 |
| Lander, CM | 1 |
| Eadie, MJ | 1 |
| Vanya, M | 1 |
| Devosa, I | 1 |
| Szok, D | 1 |
| Bártfai, G | 1 |
| Tekcan, A | 1 |
| Tural, S | 1 |
| Elbistan, M | 1 |
| Guvenc, T | 1 |
| Ayas, B | 1 |
| Kara, N | 1 |
| López-Fraile, IP | 1 |
| Cid, AO | 1 |
| Juste, AO | 1 |
| Modrego, PJ | 1 |
| Longo, B | 1 |
| Forinash, AB | 1 |
| Murphy, JA | 1 |
| Bonnett, LJ | 1 |
| Iniesta, I | 1 |
| Hoeritzauer, I | 1 |
| Mawhinney, E | 2 |
| Hunt, SJ | 2 |
| Craig, J | 2 |
| Terada, K | 1 |
| Inoue, Y | 1 |
| Russell, A | 1 |
| Smithson, WH | 1 |
| Parsons, L | 1 |
| Morrison, PJ | 1 |
| Liggan, B | 1 |
| Delanty, N | 1 |
| Long, L | 1 |
| Briggs, DE | 1 |
| French, JA | 1 |
| Johannessen, SI | 1 |
| Helde, G | 1 |
| Brodtkorb, E | 1 |
| Allegaert, K | 1 |
| Lewi, L | 1 |
| Naulaers, G | 1 |
| Lagae, L | 1 |
| Tomson, T | 1 |
| Palm, R | 1 |
| Källén, K | 1 |
| Ben-Menachem, E | 1 |
| Söderfeldt, B | 1 |
| Danielsson, B | 1 |
| Johansson, R | 1 |
| Luef, G | 1 |
| Ohman, I | 1 |
| Trial | Phase | Enrollment | Study Type | Start Date | Status | ||
|---|---|---|---|---|---|---|---|
| Levetiracetam Treatment of Neonatal Seizures: A Multi-Centre Randomized Blinded Controlled Study of the Efficacy of Oral Levetiracetam as First Line Treatment for Neonatal Seizures in China[NCT02550028] | Phase 1/Phase 2 | 60 participants (Actual) | Interventional | 2015-09-01 | Terminated (stopped due to The study was concluded as planned upon reaching its predetermined endpoint, which included the completion of data collection and achievement of the necessary sample size for statistical significance.) | ||
| Study of Maternal Pharmacokinetic and Placental Transfer of Levetiracetam[NCT04117425] | 50 participants (Anticipated) | Interventional | 2022-04-20 | Recruiting | |||
| [information is prepared from clinicaltrials.gov, extracted Sep-2024] | |||||||
4 reviews available for piracetam and Complications, Pregnancy
| Article | Year |
|---|---|
Is carbamazepine a human teratogen?
Topics: Abnormalities, Drug-Induced; Adult; Anticonvulsants; Australia; Carbamazepine; Epilepsy; Female; Fet | 2016 |
[Preconceptional and perinatal challenges of pregnancy in women with epilepsy].
Topics: Adult; Amines; Anticonvulsants; Benzodiazepines; Carbamazepine; Cyclohexanecarboxylic Acids; Epileps | 2016 |
Levetiracetam use in pregnancy.
Topics: Anticonvulsants; Clinical Trials as Topic; Dose-Response Relationship, Drug; Drug Monitoring; Epilep | 2009 |
Levetiracetam safety profiles and tolerability in epilepsy patients.
Topics: Abnormalities, Drug-Induced; Adolescent; Adult; Age Factors; Aged; Animals; Anticonvulsants; Astheni | 2004 |
14 other studies available for piracetam and Complications, Pregnancy
| Article | Year |
|---|---|
In utero exposure to levetiracetam vs valproate: development and language at 3 years of age.
Topics: Adult; Anticonvulsants; Child Development; Child, Preschool; Epilepsy; Female; Humans; Language Deve | 2014 |
Increased levetiracetam clearance associated with a breakthrough seizure in a pregnant patient receiving once/day extended-release levetiracetam.
Topics: Adolescent; Anticonvulsants; Delayed-Action Preparations; Female; Humans; Infant, Newborn; Levetirac | 2014 |
[Position Statement of Hungarian Epilepsy League: The use of valproate preparations for epilepsy in pregnancy and in women of childbearing age].
Topics: Adolescent; Adult; Anticonvulsants; Cognition; Contraception; Dose-Response Relationship, Drug; Drug | 2015 |
Evaluation of apoptotic cell death on liver and kidney tissues following administration of levetiracetam during prenatal period.
Topics: Animals; Animals, Newborn; Anticonvulsants; Apoptosis; Chi-Square Distribution; DNA Nucleotidylexotr | 2017 |
Levetiracetam plasma level monitoring during pregnancy, delivery, and postpartum: clinical and outcome implications.
Topics: Adult; Anticonvulsants; Epilepsy; Female; Follow-Up Studies; Humans; Lamotrigine; Levetiracetam; Mat | 2009 |
Child development following in utero exposure: levetiracetam vs sodium valproate.
Topics: Anticonvulsants; Child Development; Child, Preschool; Cognition; Epilepsy; Female; Humans; Infant; L | 2011 |
Carbamazepine in pregnancy: Levetiracetam and lamotrigine are better options.
Topics: Abnormalities, Drug-Induced; Anticonvulsants; Carbamazepine; Contraindications; Epilepsy; Female; Hu | 2011 |
Increased levetiracetam clearance in pregnancy: is seizure frequency affected?
Topics: Anticonvulsants; Female; Humans; Levetiracetam; Piracetam; Pregnancy; Pregnancy Complications; Seizu | 2012 |
[Clinical application of newer anti-epileptic drugs].
Topics: Amines; Anticonvulsants; Cyclohexanecarboxylic Acids; Epilepsy; Female; Fructose; Gabapentin; gamma- | 2012 |
Levetiracetam in pregnancy: results from the UK and Ireland epilepsy and pregnancy registers.
Topics: Abnormalities, Drug-Induced; Adult; Anticonvulsants; Drug Therapy, Combination; Epilepsy, Generalize | 2013 |
Levetiracetam monotherapy during pregnancy: a case series.
Topics: Abnormalities, Drug-Induced; Anticonvulsants; Epilepsy; Female; Humans; Infant, Newborn; Levetiracet | 2003 |
Levetiracetam concentrations in serum and in breast milk at birth and during lactation.
Topics: Anticonvulsants; Breast Feeding; Epilepsy; Female; Fetal Blood; Humans; Infant, Newborn; Lactation; | 2005 |
Levetiracetam pharmacokinetics in neonates at birth.
Topics: Amniotic Fluid; Anticonvulsants; Epilepsy, Complex Partial; Female; Fetal Blood; Half-Life; Humans; | 2006 |
Pharmacokinetics of levetiracetam during pregnancy, delivery, in the neonatal period, and lactation.
Topics: Anticonvulsants; Breast Feeding; Delivery, Obstetric; Epilepsy; Female; Fetal Blood; Half-Life; Huma | 2007 |